Literature DB >> 26049383

Thiazides in advanced chronic kidney disease: time for a randomized controlled trial.

Arjun D Sinha1, Rajiv Agarwal.   

Abstract

PURPOSE OF REVIEW: Chronic kidney disease is common, associated with increased cardiovascular risk, and frequently complicated by hypertension, requiring multiple agents for control. Thiazides are naturally attractive for use in this population; unfortunately, they are classically thought to be ineffective in advanced chronic kidney disease based on both theoretical considerations and the earliest studies of these agents. This report reviews the studies of thiazide use in chronic kidney disease since the 1970s, including five randomized controlled trials, all of which report at least some degree of efficacy. RECENT
FINDINGS: Two recent studies add further evidence for the utility and efficacy of thiazides in chronic kidney disease. Of these two, one used gold standard ambulatory blood pressure monitoring in patients with poorly controlled hypertension and advanced chronic kidney disease and found chlorthalidone reduces blood pressure. The second is the largest study to date of thiazides in chronic kidney disease; adding a fixed low-dose chlorthalidone as the first diuretic to the antihypertensive regimen improved blood pressure.
SUMMARY: These numerous small but positive studies reinforce the need for a randomized trial to demonstrate safety and efficacy of thiazides in advanced chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26049383     DOI: 10.1097/HCO.0000000000000188

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  6 in total

1.  Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD.

Authors:  Arjun D Sinha; Rajiv Agarwal
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-13       Impact factor: 8.237

2.  A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease.

Authors:  Dominique M Bovée; Wesley J Visser; Igor Middel; Anneke De Mik-van Egmond; Rick Greupink; Rosalinde Masereeuw; Frans G M Russel; A H Jan Danser; Robert Zietse; Ewout J Hoorn
Journal:  J Am Soc Nephrol       Date:  2020-01-29       Impact factor: 10.121

Review 3.  Revisiting diuretic choice in chronic kidney disease.

Authors:  Sehrish Ali; Sankar D Navaneethan; Salim S Virani; L Parker Gregg
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-07-11       Impact factor: 3.416

4.  Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.

Authors:  Rajiv Agarwal; Arjun D Sinha; Andrew E Cramer; Mary Balmes-Fenwick; Jazmyn H Dickinson; Fangqian Ouyang; Wanzhu Tu
Journal:  N Engl J Med       Date:  2021-11-05       Impact factor: 176.079

5.  Resistant Hypertension in CKD.

Authors:  George Thomas; Mahboob Rahman
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-08       Impact factor: 8.237

6.  Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial.

Authors:  Fabio Solis-Jimenez; Lucia Monserrat Perez-Navarro; Ricardo Cabrera-Barron; Jesus Antonio Chida-Romero; Geovana Martin-Alemañy; Edgar Dehesa-López; Magdalena Madero; Rafael Valdez-Ortiz
Journal:  BMC Nephrol       Date:  2022-09-20       Impact factor: 2.585

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.